Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030
New mass spectrometry instrument and consumables launch during IMSC 2022
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Commits to plant 5000 trees in phase 1 with its partner SankalpTaru Foundation
Subscribe To Our Newsletter & Stay Updated
